WILL KEEP EYES ON THIS 1.. I LIKE THE BALANCE SHEET GROWTH.. P/E IS BIT HIGH .WILL WAIT FOR FURTHER DROP
MSB Mesoblast resubmits US FDA application for approval of Ryoncil in children with graft vs host disease; shares dip -4%